Continue encorafenib and binimetinib after prior trial benefit
Part of Cancer clinical trials.
This study lets people who previously took encorafenib and binimetinib continue those same medicines if they are benefiting and side effects are not severe. It’s meant to help participants stay on treatment safely while the original trial is completed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking encorafenib plus binimetinib from a previous study and your doctor thinks it’s helping you.
- Your side effects have not reached severe levels: no related Grade 3 or higher side effects.
- If you had side effects that were Grade 2, they must not be considered “intolerable” or related to the study medicine.
- You must agree to the trial’s pregnancy prevention rules (for you and/or your partner) as outlined in the continuation study.
- There must be no medical or safety reason your doctor or the study team believes would prevent you from joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
This trial tests adding a new chemotherapy regimen (FOLFIRI) to the combination of Encorafenib and Cetuximab for people with a specific type of advanced colorectal cancer that has started growing again after initial treatment with Encorafenib and Cetuximab. The goal is to see if the new combination can help control the cancer longer.
This trial studies how doctors use encorafenib plus binimetinib for real-world care in people with BRAF V600–mutated melanoma that can’t be removed by surgery or has spread. It may help improve understanding of which patients benefit and what happens in everyday clinical practice.
This trial tests whether giving encorafenib and cetuximab before surgery can shrink or control BRAF-mutated colon or upper rectal cancer and make surgery more effective. It also checks whether this approach is safe and helps patients do better overall.
This trial tests whether giving the targeted therapy combination encorafenib (a BRAF inhibitor) plus cetuximab (an anti-EGFR antibody) again can help people whose metastatic colorectal cancer has a BRAF V600E mutation and whose disease progressed after a prior response to a similar treatment.
This trial is testing a combination of two targeted drugs (encorafenib and cetuximab) with standard chemotherapy before surgery in people with a specific type of colorectal cancer that has the BRAF V600E mutation and is locally advanced or has limited spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.